secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0001370053-22-000017
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio CEO Hamza Suria resigns; Daniel Faga named Interim President and CEO
-------------------------------------------------------------------------------

- Hamza Suria resigned as President, CEO and Class II director effective March 20, 2022.
- Suria receives $603,580 salary continuation for 12 months and COBRA reimbursement; consulting through March 2023.
- Daniel Faga, former Mirati COO and Spark CBO, appointed Interim CEO effective March 21, 2022.
- Faga receives base salary $603,580, 55% target bonus, and 887,043 RSUs vesting over 24 months.
- Faga's RSU vests fully on change of control termination or if new CEO hired; severance includes 12 months salary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005322000017/0001370053-22-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005322000017/anab-20220320.htm
  HTML page:      https://secwatch.observer/filing/0001370053-22-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer